Mind Medicine's (MNMD) Recent Achievements Boosting Stock
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $16
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
Mind Medicine Price Target Cut to $16.00/Share From $27.00 by Baird
Mind Medicine Is Maintained at Outperform by Baird
Baird Maintains Outperform on Mind Medicine, Lowers Price Target to $16
Analysts' Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (MNMD), SurModics (SRDX) and Enhabit, Inc (EHAB)
Chardan Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20
RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Elevation Oncology (ELEV) and Xeris Pharmaceuticals (XERS)
Mind Medicine Analyst Ratings
H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55
Mind Medicine's Promising Future: Buy Rating Backed by Strong Phase 3 Prospects and Financial Position
10-K: FY2024 Annual Report
8-K: MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
MIND MEDICINE Earnings Results: $MNMD Reports Quarterly Earnings
Mind Medicine GAAP EPS of -$0.41 Misses by $0.11
Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120...
Mind Medicine MindMed 4Q Research and Development Expenses $21.8M >MNMD